Multiple Sclerosis Clinical Trials in New York

40 recruiting studies across 1 city

Browse by City

All Trials in New York

Phase

Trial	Phase	Sponsor	Dist.
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)	—	TG Therapeutics, Inc.	<1 mi
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis	Phase 3	Sanofi	<1 mi
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer	Phase 1	National Cancer Institute (NCI)	<1 mi
Study of COYA 302 for the Treatment of ALS	Phase 2	Coya Therapeutics	<1 mi
TSC Biosample Repository and Natural History Database	—	National Tuberous Sclerosis Association	<1 mi
NYSCF Scientific Discovery Biobank	—	New York Stem Cell Foundation Research Institute	<1 mi
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis	Phase 1	AstraZeneca	<1 mi
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)	Phase 1	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	<1 mi
Task Specific Training for Advanced Multiple Sclerosis	N/A	Hunter College of City University of New York	<1 mi
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders	Phase 1	TG Therapeutics, Inc.	<1 mi
A Study of the MIND Diet for Persons With Multiple Sclerosis	N/A	Icahn School of Medicine at Mount Sinai	<1 mi
A Study of AZD0120 in Autoimmune Diseases	Phase 1	AstraZeneca	<1 mi
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis	Phase 4	National Institute of Allergy and Infectious Diseases (NIAID)	<1 mi
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab	Phase 3	TG Therapeutics, Inc.	<1 mi
Effect of Cooling on Balance Performance in Multiple Sclerosis	—	Hunter College of City University of New York	<1 mi
Home-Based Transcranial Direct Current Stimulation (tDCS) for Depression in Multiple Sclerosis (MS)	Phase 2	NYU Langone Health	<1 mi
A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients	Phase 2	Tiziana Life Sciences LTD	<1 mi
PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS	Phase 2	PhenoNet, Inc.	<1 mi
Vancomycin Study in Multiple Sclerosis (MS)	Phase 1	Icahn School of Medicine at Mount Sinai	<1 mi
A Palliative Care Model Impact on Knowledge and Attitudes	N/A	Hunter College of City University of New York	<1 mi
Eccentric Exercise and Fatigue in Multiple Sclerosis	—	Hunter College of City University of New York	<1 mi
Noninvasive Vagal Nerve Stimulation	N/A	NYU Langone Health	<1 mi
Genes and Environment in Multiple Sclerosis	—	Columbia University	<1 mi
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)	Phase 3	National Institute of Allergy and Infectious Diseases (NIAID)	<1 mi
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses	Phase 2	Reunion Neuroscience Inc	<1 mi
Effectiveness of Task Specific Home Exercise Program	N/A	New York Presbyterian Brooklyn Methodist Hospital	5 mi
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis	Phase 3	Sanofi	12 mi
Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis	—	Hoffmann-La Roche	12 mi
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy	Phase 1/2	UniQure Biopharma B.V.	12 mi
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis	Phase 3	Celgene	13 mi
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.	Phase 3	Novartis Pharmaceuticals	13 mi
Examining Effects of Ocrevus on Cognitive Fatigue Using fMRI	—	Kessler Foundation	14 mi
An Examination of Cognitive Fatigue Using Functional Neuroimaging	—	Kessler Foundation	14 mi
Examining Effects of Tysabri on Cognitive Fatigue Using fMRI	—	Kessler Foundation	14 mi
Investigating the Effects of Wearable Robotic Exoskeleton for Improving Mobility and Cognition in Persons With MS	N/A	Kessler Foundation	14 mi
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)	Phase 3	Amgen	16 mi
Meeting an Unmet Need in Multiple Sclerosis	N/A	Kessler Foundation	20 mi
Testing the Feasibility of Computer-based Cognitive Training in Individuals with Multiple Sclerosis Living in the Community	N/A	Kessler Foundation	20 mi
A Novel Combinatory Approach to Maximize Functional Recovery of Learning and Memory in Multiple Sclerosis	N/A	Kessler Foundation	20 mi
Neurologic Stem Cell Treatment Study	N/A	MD Stem Cells	45 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.